Brokerages Set Scholar Rock Holding Co. (NASDAQ:SRRK) Price Target at $42.67

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have been given an average rating of “Buy” by the six research firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $42.67.

Separately, Wedbush reissued an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $31.06 on Friday. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The firm’s 50-day simple moving average is $31.75 and its 200 day simple moving average is $35.81. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -13.22 and a beta of 0.37.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 5,000 shares of the business’s stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the completion of the transaction, the insider now owns 71,750 shares of the company’s stock, valued at approximately $2,355,552.50. The trade was a 6.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. The trade was a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 255,231 shares of company stock valued at $9,220,236. Corporate insiders own 13.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. FMR LLC increased its holdings in Scholar Rock by 33.7% in the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock worth $589,316,000 after purchasing an additional 3,439,215 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company’s stock valued at $401,231,000 after buying an additional 629,315 shares during the period. Vanguard Group Inc. raised its holdings in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock valued at $205,013,000 after buying an additional 708,817 shares during the last quarter. Marshall Wace LLP grew its holdings in Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the last quarter. Finally, Bellevue Group AG increased its position in Scholar Rock by 16.2% in the 4th quarter. Bellevue Group AG now owns 2,510,690 shares of the company’s stock valued at $108,512,000 after acquiring an additional 349,487 shares during the period. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.